A week after the World Health Organisation (WHO) granted Emergency Use Listing (EUL) to Covaxin, a prestigious medical journal Lancet has stated that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19. Its efficacy data also demonstrates 70.8% protection against all variants of SARS-CoV-2.
from India News | Latest News Headlines & Live Updates from India - Times of India https://ift.tt/30aDSMa
via IFTTT
Post Top Ad
Thursday 11 November 2021
Home
India News
India News | Latest News Headlines & Live Updates from India - Times of India
Covaxin well tolerated, phase 3 data shows 77.8% efficacy against symptomatic Covid: Lancet
Covaxin well tolerated, phase 3 data shows 77.8% efficacy against symptomatic Covid: Lancet
Tags
# India News
# India News | Latest News Headlines & Live Updates from India - Times of India
Share This
About News Now Live
India News | Latest News Headlines & Live Updates from India - Times of India
Subscribe to:
Post Comments (Atom)
Post Bottom Ad
If you require any more information or have any questions about our site's disclaimer, please feel free to contact us by email at newsnowlive.tv@gmail.com
No comments:
Post a Comment